Novel and traditional anthropometric indices for identifying metabolic syndrome in non-overweight/obese adults

Lihong Wu  
Zhejiang University School of Medicine Sir Run Run Shaw Hospital General Practice Department 
https://orcid.org/0000-0002-1903-6981

WenHua Zhu  
Zhejiang University School of Medicine Sir Run Run Shaw Hospital General Practice Department

Qiaohua Qiao  
Zhejiang University School of Medicine Sir Run Run Shaw Hospital General Practice Department

Lijuan Huang  
Zhejiang University School of Medicine Sir Run Run Shaw Hospital General Practice Department

Yiqi Li  
Zhejiang University School of Medicine Sir Run Run Shaw Hospital General Practice Department

Liying Chen (✉ 3197020@zju.edu.cn)

Research

Keywords: anthropometric indice, metabolic syndrome, non-overweight/obese, cardiovascular disease

DOI: https://doi.org/10.21203/rs.3.rs-52907/v2

License: ©  This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

Background: Metabolic syndrome (MetS) in non-overweight/obese people is insidiously associated with cardiovascular disease (CVD). Novel anthropometric indices can reflect central obesity better than the traditional anthropometric indices. Therefore, we hypothesize that these newly developed anthropometric indices can better identify MetS in non-overweight/obese people than conventional indices.

Methods: Cross-sectional data of sociodemographic, biochemical and anthropometric indices were collected from 2916 non-overweight/obese Chinese people. A body shape index (ABSI), body roundness index (BRI), waist-to-height ratio (WHtR), weight-adjusted-waist index (WWI) and abdominal volume index (AVI) were calculated. Partial correlation analysis was used to clarify the correlation between anthropometric indices and MetS variables. Binary logistic regression analysis was applied to assess the association between anthropometric indices and MetS and its components. Receiver-operating characteristic (ROC) curve was used to identify the diagnostic ability of anthropometric indices for MetS and its components. The area under curve (AUC) difference between WHtR and each new anthropometric index was compared in pairs.

Results: After adjusting for covariates, AVI had the optimal ability of identifying MetS (AUC: 0.743 for male, 0.819 for female) and the strongest correlation with high-density lipoprotein cholesterol (HDL-C) (coe: -0.227 for male, -0.207 for female) and the highest odds ratios (OR) with low HDL-C group (male: OR=1.37, female: OR=1.55). The WHtR was comparable to BRI in assessing MetS (AUC: 0.739 for male, 0.817 for female). WHtR or BRI could also well identify hypertension (AUC: 0.602 for male, 0.688 for female) and dysglycemia (AUC: 0.669 for male, 0.713 for female) and female's high triglyceride level (AUC 0.712). The recognition ability of the two was equivalent. The ability of ABSI and WWI to identify MetS was weak.

Conclusions: AVI is the optimal anthropometric indices to identify MetS in non-overweight/obese Chinese adults. BRI and WHtR can also be considered as discriminators, while ABSI and WWI are weak discriminators. WHtR is easy to measure. So, it is recommended as an early preliminary screening method for the MetS in non-overweight/obese people.

Introduction

MetS is a cluster of cardiometabolic risk, including dysglycemia, elevated blood pressure, raised triglyceride levels, low high-density lipoprotein cholesterol levels, and central adiposity. Previous studies have found that at least one in four adults have MetS worldwide (1). Since the risk of arteriosclerotic cardiovascular disease (ASCVD) in people with MetS is twice than that of non-MetS, people with MetS may account for half of all ASCVD (2). In addition, MetS increased the likelihood of type 2 diabetes fivefold (2). Although the incidence of MetS has been closely associated with obesity (3), metabolic disorders are often hidden in non-overweight/obese people (4-9), especially in Asians (8). The China National Diabetes and Metabolic Disorders Study (9) found that metabolic disorders accounted for 46.2% of people with normal weight.

Visceral fat plays a critical role in MetS pathogenesis (10). Since visceral fat is mainly concentrated in the abdomen, for a long time, people have simply screened and managed visceral obesity through central obesity anthropometric indices, such as waist circumference (WC), body mass index (BMI) and WHtR (11). However, some studies found that these indices provide limited information about fat distribution. BMI is a rough indices of obesity since individuals with similar BMI may present with different degree of fatness (12). Whereas WC is unclear what extent depending on body size (13). WHtR has been shown to be superior to BMI and WC in screening central obesity (14-16). Studies has shown that it was well correlated with a variety of cardiometabolic components (17), which was not supported by others (18). Therefore, it is necessary to design more suitable anthropometric indices that combine body shape and disease prediction ability to measure central obesity.
BRI, ABSI and AVI were all novel indices of body geometry and good predictors of visceral fat (19-21). BRI was optimal in identifying the metabolic components and arteriosclerosis of overweight/obese people (22-24). ABSI has been shown to be associated with visceral fat, carotid atherosclerosis (25) and obesity-related death risk independent of BMI and WC (20). AVI indirectly reflected visceral fat content through assessing of the entire abdominal volume. It is closely related to impaired fasting glucose (IGT) and diabetes mellitus (DM) (26), and has good predictive ability for MetS (27). WWI was a unique obesity index which was found by Yousung Park et al in a study of 465,629 South Koreans in 2018 (28). It had excellent predictive power for cardiometabolic disease, CVD and all-cause mortality risk. These four indices have a strong ability to identify MetS in terms of body shape and disease identification ability. However, whether these new anthropometric indicators are superior to traditional anthropometric indicators and whether they can better identify MetS in non-overweight/obese people needs further research.

Thus, the current study was designed to compare conventional and novel indices for identifying MetS in non-overweight/obese Chinese adults. Meanwhile, we tried to screen out the most suitable anthropometric indices for MetS in non-overweight/obese Chinese adults and the optimal cut-off point based on different genders.

**Methods**

**Study population**

In the present study, 4790 participants who underwent routine check-ups were recruited from June 2018 to June 2019 at the check-ups center of Sir Run Run Shaw Hospital, affiliated with Medical College of Zhejiang University. All participants were Han ethnicity and came from more than 30 provinces in mainland China. Each participant finished a standard questionnaire which included information on age, body weight, disease history, medication history, and family history of cardiometabolic diseases and CVD. Inclusion criteria were BMI <24 kg/m² and age between 18 and 75 years. Exclusion criteria were: (1) a history of corticosteroid or hormone therapy in the past 6 months; (2) those who have received weight loss program or lost weight ≥5% in the past 12 months; (3) a history of cardiovascular and cerebrovascular disease, heart failure, arrhythmia, malignant tumor, edema, viral hepatitis, cirrhosis, hepatic and renal insufficiency, thyroid dysfunction, skeletal malformation or amputation or dependence on a wheelchair or other mobile assistance device; (4) more than 14 units of alcohol per week for males (1 unit = 14 grams of alcohol) and more than 10 units per week for females; (5) pregnancy. Finally, 2,916 subjects (1,215 males and 1,701 females) were recruited. After fasting for one night, all subjects completed blood sample collection, anthropometric measurements and a short questionnaire.

The study was approved by the Ethics Committee of Sir Run Run Shaw Hospital, affiliated with Medical College of Zhejiang University. All participants provided written informed consent before taking part in the study.

**Anthropometric measurements**

Body height and weight were measured on the digital scale with light clothing and no shoes with the accuracy 0.1cm and 0.1kg, respectively. WC was measured at the end of a normal exhalation by placing a tape measure on the horizontal surface between the lower rib and the iliac crest, at the accuracy of 0.1cm. Hip circumference was measured at the maximum extension of the hip bone. WHtR was calculated as WC(cm)/ height(cm). BMI was obtained by dividing the participant's weight (kg) by a square of height (m²). BRI, WWI, AVI and ABSI were calculated according to the following formula (19-21, 28):
Clinical and biochemical tests

Blood pressure was monitored using a standard sphygmomanometer (OMRON 705IT). After the subjects sat for 10 minutes, the researchers took two blood pressure records from their right arms. The average value of the two data was used for statistical analysis. The ARCHITECT C16000 chemical analyzer was used to measure fasting blood glucose (FBG), uric acid (UA), C-reactive protein (CRP), total cholesterol (TCHO), low-density lipoprotein cholesterol (LDL-C), HDL-C and triglyceride (TG) in a standard laboratory according to standard procedures.

Definition of MetS

In the present study, MetS was diagnosed in accordance with the definition of the Chinese guidelines for the Prevention and Treatment of dyslipidemia in adults (2016 revision) (29). The participants were categorized as MetS when they met three or more of the following components: (1) abdominal obesity: WC ≥ 90 cm for males or ≥ 85 cm for females; (2) Hyperglycemia: fasting blood glucose ≥ 6.10mmol/L (110mg/dl) or blood glucose ≥ 7.80mmol/L (140mg/dl) 2 hours after glucose load and/or diabetes had been diagnosed and treated; (3) Hypertension: blood pressure ≥ 130/85 mmHg and/or hypertension has been diagnosed and treated; (4) Fasting TG ≥ 1.7mmol/L (150mg/dl); (5) Fasting HDL-C < 1.0 mmol/L (40 mg/dl).

Statistical analysis

SPSS 23.0 (IBM) was used for statistical analysis and MedCalc Version19.1 for ROC curve comparison. Data was described as mean and standard deviation for continuous variables and as frequencies and percentage for categorical variables. The study subjects were characterized by independent sample t-test, nonparametric test (continuous variable) or χ² test (categorical variables) according to gender. Partial correlation analysis was applied to evaluate the correlation between various anthropometric indexes and metabolic variables such as systolic blood pressure (SBP), (diastolic blood pressure) DBP, TG, HDL-C and FBG. Binary logistic regression analysis assessed the relationship between anthropometric indicators and MetS and its components. Age and CRP were adjusted by partial correlation analysis and binary logistic regression analysis, and z-scores of anthropometric indices were used. The ROC and AUC were used to assess the ability of five anthropometric indices to identify MetS and its components. Method described by Hanley and McNeil(30) was used to assess AUC differences in MetS among BRI, WWI, AVI, ABSI and WHtR. Finally, the optimal cut-off values of five anthropometric indicators for MetS identification were determined. P< 0.05 was considered statistically significant.

Results

The demographic characteristics, clinical and anthropometric data of the study population

A total of 2,916 non-overweight/obese subjects (1,215 for male and 1,701 for female) participated in the study. The prevalence of MetS was 4.9% (7.6% in males and 3.0% in females), and the prevalence of dyslipidemia (21.65%) and hypertension (22.7%) was higher. Physical measurement indicators (height, weight, BMI, WC, Whtr, BRI, AVI, ABSI, WWI, AVI), clinical indicators (SBP, DBP, FBG, TC, TG, LDL-C, CRP, UA) and the incidence of MetS and its components were significantly higher in males than in females (except HDL-C).
Partial correlation between different anthropometric indices and metabolic variables

After adjusting for age, UA and CRP, most anthropometric measures were significantly correlated with metabolic variables. The correlation between BRI, WHtR, AVI and metabolic variables was stronger than that between ABSI and WWI. AVI had the strongest negative correlation with HDL-C (coe: -0.192 for males and females). ABSI showed the weakest correlation.

Binary logistic regression analysis of anthropometric indicators and MetS and its components

The OR and 95% confidence interval (CI) were analyzed using anthropometric Z-scores after controlling age, UA and CRP. WHtR, AVI, BRI were independently correlated with MetS and its components. These five anthropometric indexes had the high OR for MetS, among which WHtR had the highest dominance ratio in females (OR=2.812, P<0.001) and AVI had the highest dominance ratio in males (OR=2.45, P<0.001). The OR of ABSI for MetS was the lowest (males OR=1.607, P<0.001; females OR=2.068, P<0.001).

The diagnostic ability of anthropometric indicators for MetS and its components

As shown in Table 4 and Fig 1, AVI had the best ability to identify MetS (AUC: 0.743 for male, 0.819 for female) and low HDL-C (AUC: 0.591 for male, 0.614 for female). The recognition of WHtR and BRI for MetS were similar (AUC: 0.739 for males and 0.817 for females).

The differences in ROC curves of anthropometric indices for MetS identification

There were no statistically significant differences between AVI with WHtR and BRI, while there were significant differences between WHtR with ABSI and WWI. The ability of WHtR to identify MetS was comparable to that of BRI and AVI, but significantly superior to that of ABSI and WWI(Table 4&5).

The optimal cutoff value of sex-based anthropometric indices for the identification of MetS

The optimal cut-off value of each anthropometric index for evaluating MetS included WHtR (0.571 for males and 0.49 for females), BRI (3.41 for males, 3.24 for females), AVI (14.47 for males, 12.83 for females). When the optimal cutoff point value was obtained, AVI showed the highest sensitivity (0.717) to identify MetS in men and the highest specificity (0.823) in women. WHtR had the highest specificity (0.76) for screening MetS in men and the highest sensitivity for identifying women (0.766) (Table 6).

Discussion

To date, there have been only a few studies of anthropometric indicators of MetS recognition in non-overweight/obese people, and the results are not consistent with the latest anthropometric indicators. This cross-sectional study innovatively compared the identification ability of the novel central obesity index with traditional indicators for non-overweight/obese individuals with a large sample size and a larger population coverage. The results demonstrate that the novel anthropometric index can identify MetS in non-overweight/obese people. Among them, AVI had the best ability to identify MetS and low HDL-C in different genders.

A growing number of studies showed that cardiometabolic disease often occurs in people with normal weight(4-6, 9). Visceral adipose tissue (VAT) accumulation is a major cause (31). Clinicians often use anthropometric indices which reflect VAT to screen MetS in large populations. For a long time, BMI combined with WC has been extensively used to assess central obesity. But both two predicted all-cause mortality in the opposite way in some cases (32). The paradox occurs when the distinction of body fat is not made to predict cardiometabolic risk (12). Therefore, the assessment of central obesity and the prediction of cardiometabolic disease by BMI combined with WC are limited. In this study, people with
BMI<24 kg/m² were taken as the study subjects, and MetS was taken as the disease, avoiding the assessment of BMI combined with WC.

WHtR, another widely used traditional anthropometric index, is superior to BMI and WC in the assessment of central obesity (14-16, 33). As a simple and effective anthropometric index, it has been recommended by many scholars as a screening tool for cardiometabolic risk factors. Even in people with normal BMI and/or WC, WHtR can effectively identify cardiometabolic disease (34, 35). However, meta-analysis based on Embase and Medline databases showed that WHtR was not superior to other anthropometric indicators in distinguishing MetS and other cardiometabolic factor (18). Moreover, these studies did not compare WHtR with sundry new anthropometric indexes such as WWI and AVI, and it was still uncertain whether the WHtR in non-overweight/obese people is the optimal anthropometric index to screen MetS.

Unlike the traditional anthropometric index, the new anthropometric index mostly started from the geometric model of the human body, reflected the VAT of the body in a three-dimensional way. Based on waist and hip circumference, AVI calculated the entire abdominal volume from symphysis of pubis to xiphoid appendix (26), theoretically including abdominal free fat and adipose tissue volumes, which are the main distribution areas of visceral fat (36). VAT has fewer insulin receptors distributed on the cell surface, decreased insulin receptor substrate protein-1 expression, and reduced insulin receptor affinity. Therefore, VAT becomes less sensitive to insulin and has lower sugar uptake and utilization (37). In addition, free fatty acid produced by VAT lipolysis affects insulin signaling pathway, reduces the sensitivity of liver and skeletal muscle to insulin, inhibits glucose uptake and oxidation, and aggravates glucose regulation disorders (38). Therefore, AVI demonstrated excellent predictive power for IGT and DM by fully evaluating VAT (26). Previous study found that the predictive ability of AVI for MetS was better than other new anthropometric indicators and traditional indicators (39, 40), and was the strongest predictor [1], which was similar to the results of this study. In this study, AVI's ability to identify MetS in non-overweight/obese people was lower than that in Spanish adolescents (AUC: 0.831 for males, 0.867 for females) (39), but higher than that in northern Iran (AUC: 0.72 for males, 0.73 for females). This was related to race, age and BMI range of the study population (41, 42).

This study found that BRI and WHtR had similar ability to screen MetS, which were similar to the results of previous studies (23, 43). WHtR reflects central obesity through simple numerical comparison, which overcomes the influence of height on VAT (44). However, BRI is a human body ellipse model, which evaluates body fat rate and VAT according to roundness and eccentricity (19) and quantifies individual body shape in an independent manner of height. Although the two anthropometric indicators have different principles, they are all derived from WC and height. VAT assessment is also based on WC and abdominal fat volume. Therefore, BRI and WHtR had the similar recognition capability for MetS, but they had no statistical difference with AVI. Compared with AVI and BRI, WHtR is easier to obtain and more suitable for early preliminary screening in a large population.

WWI is a recently developed unique obesity index based on weight and WC (28), which can predict the incidence and mortality of obesity-related diseases with a linear trend, avoiding the U-shaped relationship between BMI and CVD mortality. Until now, there have been no studies on the recognition capability of WWI for MetS and no studies on the prognosis of metabolic diseases in non-overweight/obese people. Our study found that WWI was less able to identify MetS in non-overweight/obese people than WHtR. It was speculated that WWI was based on body weight and WC and it could not distinguish fat distribution and body weight composition, so the fat content was underestimated. Since height was not taken into account, WWI usage may underestimate the VAT of short subjects and overestimate the VAT of tall subjects, thus misleading the diagnosis of central obesity and failing to predict the prevalence of MetS. ABSI is another body shape index based on WC, weight and height (20). At a given height and weight, high ABSI means WC is higher than expected, which is a good indicator of central obesity. ABSI changes the limitations of WC as a BMI dependent index (20). Studies have shown that ABSI can identify visceral obesity and sarcopenic obesity in overweight/obese adults with T2DM (45). However, this study showed that, similar to WWI, ABSI was also weak in predicting MetS in non-overweight/obese people. Similar findings have been found in other studies (46, 47). It is speculated that although these two indexes are new obesity indexes, both the
establishment and verification of the prediction model are to make up for the deficiency of BMI in the prediction of obesity-related mortality risk, and the identification of MetS may affect its diagnostic efficacy. To realize the screening of MetS or cardiometabolic disease, further formulation and a large sample population studies are needed.

In addition, anthropometric indices were better at identifying MetS in females than in males after adjusting for confounding factors. This cannot be explained by conventional wisdom, which males have more visceral fat and females have more subcutaneous adipose tissue (41). This may be related to the large number of female subjects. Further studies on the predictive power of novel anthropometric indicators for MetS of different genders are needed.

Currently, the novel anthropometric indicators have shown advantages in various fields. They are worthy of clinical and public health promotion for their ability to predict obesity-related diseases and deaths at an earlier stage, but new longitudinal studies are needed in a broader population to further explore their predictive power.

Our study has several limitations. First, this was a cross-sectional study and it cannot reflect causality. Second, information on the lifestyle and drug therapy of the participants was not obtained in the study. These indices were all derived from WC. These may confound the relationship between anthropometric indices and MetS. Third, the participants were volunteers who were more concerned about their health and who might have a history of CVD or family history. Finally, we did not measure 2 hours postprandial blood glucose, which may lead to under diagnosis in some diabetes patients.

Conclusions

Despite the limitations of the study, our research results showed that AVI was the optimal anthropometric index for the identification of MetS in non-overweight/obese Chinese adults. BRI and WHtR can also be taken into account as discriminators, while ABSI and WWI are weak discriminators. WHtR was simple and easy to measure. It was recommended as an early primary screening method for MetS in non-overweight/obese people.

Abbreviations

WC: waist circumference; WtHR: waist-to-height ratio; BMI: body mass index; AVI: abdominal volume index; ABSI: a body shape index; WWI: weight adjusted waist index; BRI: body roundness index; SBP: systolic blood pressure; DBP: diastolic blood pressure; FBG: fasting blood glucose; TC: total cholesterol; TG: triglyceride; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; CRP: C-reactive protein; UA: uric acid; MetS: metabolic syndrome; CVD: cardiovascular disease; ASCVD: arteriosclerotic cardiovascular disease; IGT: impaired fasting glucose; VAT: visceral adipose tissue; DM: diabetes mellitus; OR: odds ratio; CI: confidence interval; ROC: receiver-operating characteristic curve; AUC: area under the curve

Declarations

Acknowledgements

We would like to acknowledge all the staff of the Department of General Practice and Health Promotion Centre at Sir Run Run Shaw Hospital affiliated with Zhejiang University for their contributions.

Authors’ contributions

LHW designed the study, performed statistical analysis, interpreted the data and drafted the manuscript. WHZ contributed to the statistical analysis and the design of the study and edited the manuscript. LYC contributed to the conception of the study, reviewed and edited the manuscript. QHQ and LJH collected and standardized the database. YQL revised the manuscript and polished the language style. All authors read and approved the final manuscript.
Funding

The study was approved by Natural Science Foundation Public Welfare Technology Research Program of Zhejiang Province (LGF18H070003, LGF19H070006) and Health Science and Technology Planning of Zhejiang Province (2019330511, 2018KY495).

Availability of data and materials

The datasets used and analyzed during the current study available from the corresponding author on reasonable request.

Ethics approval and consent to participate

The study was approved by the Ethics Committee of Run Run Shaw Hospital, Zhejiang University. An informed written consent was obtained from each participant.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1 Department of General Practice, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China

References

1. Grundy SM. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol. 2008;28(4):629-36.
2. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640-5.
3. Saklayen MG. The Global Epidemic of the Metabolic Syndrome. Curr Hypertens Rep. 2018;20(2):12.
4. Wildman RP, Muntner P, Reynolds K, McGinn AP, Rajpathak S, Wylie-Rosett J, et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004). Archives of internal medicine. 2008;168(15):1617-24.
5. Suliga E, Koziel D, Gluszek S. Prevalence of metabolic syndrome in normal weight individuals. Ann Agric Environ Med. 2016;23(4):631-5.
6. Shea JL, King MT, Yi Y, Gulliver W, Sun G. Body fat percentage is associated with cardiometabolic dysregulation in BMI-defined normal weight subjects. Nutr Metab Cardiovasc Dis. 2012;22(9):741-7.
7. Zheng Q, Lin W, Liu C, Zhou Y, Chen T, Zhang L, et al. Prevalence and epidemiological determinants of metabolically obese but normal-weight in Chinese population. BMC Public Health. 2020;20(1):487.
8. Palaniappan LP, Wong EC, Shin JJ, Fortmann SP, Lauderdale DS. Asian Americans have greater prevalence of metabolic syndrome despite lower body mass index. International journal of obesity (2005). 2011;35(3):393-400.
9. Hou X, Chen P, Hu G, Chen Y, Chen S, Ma X, et al. Cardiometabolic Disease Is Prevalent in Normal-Weight Chinese Adults. J Am Coll Cardiol. 2016;68(14):1599-600.
10. Tchernof A, Després JP. Pathophysiology of human visceral obesity: an update. Physiol Rev. 2013;93(1):359-404.
11. Pinho CPS, Diniz ADS, de Arruda IKG, Leite A, Petribu MMV, Rodrigues IG. Predictive models for estimating visceral fat: The contribution from anthropometric parameters. PLoS One. 2017;12(7):e0178958.

12. Elagizi A, Kachur S, Lavie CJ, Carbone S, Pandey A, Ortega FB, et al. An Overview and Update on Obesity and the Obesity Paradox in Cardiovascular Diseases. Prog Cardiovasc Dis. 2018;61(2):142-50.

13. Hsieh SD, Yoshinaga H. Do people with similar waist circumference share similar health risks irrespective of height? Tohoku J Exp Med. 1999;188(1):55-60.

14. Peer N, Lombard C, Steyn K, Levitt N. Waist-to-height ratio is a useful indicator of cardio-metabolic risk in South Africa. Fam Pract. 2020;37(1):36-42.

15. Ejtahed HS, Kelishadi R, Qorbani M, Motlagh ME, Hasani-Ranjbar S, Anoorani P, et al. Utility of waist circumference-to-height ratio as a screening tool for generalized and central obesity among Iranian children and adolescents: The CASPIAN-V study. Pediatr Diabetes. 2019;20(5):530-7.

16. Ashwell M, Gunn P, Gibson S. Waist-to-height ratio is a better screening tool than waist circumference and BMI for adult cardiometabolic risk factors: systematic review and meta-analysis. Obes Rev. 2012;13(3):275-86.

17. Liu J, Tse LA, Liu Z, Rangarajan S, Hu B, Yin L, et al. Predictive Values of Anthropometric Measurements for Cardiometabolic Risk Factors and Cardiovascular Diseases Among 44 048 Chinese. J Am Heart Assoc. 2019;8(16):e010870.

18. Lo K, Wong M, Khalechelvam P, Tam W. Waist-to-height ratio, body mass index and waist circumference for screening paediatric cardio-metabolic risk factors: a meta-analysis. Obes Rev. 2016;17(12):1258-75.

19. Thomas DM, Bredlau C, Bosy-Westphal A, Mueller M, Shen W, Gallagher D, et al. Relationships between body roundness with body fat and visceral adipose tissue emerging from a new geometrical model. Obesity (Silver Spring). 2013;21(11):2264-71.

20. Krakauer NY, Krakauer JC. A new body shape index predicts mortality hazard independently of body mass index. PLoS One. 2012;7(7):e39504.

21. Guerrero-Romero F, Rodriguez-Moran M. Abdominal volume index. An anthropometry-based index for estimation of obesity is strongly related to impaired glucose tolerance and type 2 diabetes mellitus. Arch Med Res. 2003;34(5):428-32.

22. Li G, Yao T, Wu XW, Cao Z, Tu YC, Ma Y, et al. Novel and traditional anthropometric indices for identifying arterial stiffness in overweight and obese adults. Clin Nutr. 2020;39(3):893-900.

23. Liu PJ, Ma F, Lou HP, Zhu YN. Comparison of the ability to identify cardiometabolic risk factors between two new body indices and waist-to-height ratio among Chinese adults with normal BMI and waist circumference. Public Health Nutr. 2017;20(6):984-91.

24. Chang Y, Guo X, Chen Y, Guo L, Li Z, Yu S, et al. A body shape index and body roundness index: two new body indices to identify diabetes mellitus among rural populations in northeast China. BMC Public Health. 2015;15:794.

25. Geraci G, Zammuto M, Gaetani R, Mattina A, D’Ignoto F, Geraci C, et al. Relationship of a Body Shape Index and Body Roundness Index with carotid atherosclerosis in arterial hypertension. Nutr Metab Cardiovasc Dis. 2019;29(8):822-9.

26. Guerrero-Romero F, Rodríguez-Morán M. Abdominal volume index. An anthropometry-based index for estimation of obesity is strongly related to impaired glucose tolerance and type 2 diabetes mellitus. Arch Med Res. 2003;34(5):428-32.

27. Perona JS, Schmidt-RioValle J, Fernández-Aparicio Á, Correa-Rodríguez M, Ramírez-Vélez R, González-Jiménez E. Waist Circumference and Abdominal Volume Index Can Predict Metabolic Syndrome in Adolescents, but only When the Criteria of the International Diabetes Federation are Employed for the Diagnosis. Nutrients. 2019;11(6).

28. Park Y, Kim NH, Kwon TY, Kim SG. A novel adiposity index as an integrated predictor of cardiometabolic disease morbidity and mortality. Sci Rep. 2018;8(1):16753.
29. Zhu Junren, Gao Runlin, Zhao Shuiping, Lu Guoping, Zhao Dong, Li Jianjun. Chinese Guidelines for Prevention and Treatment of dyslipidemia in adults (2016 revision). Chinese Journal of Cardiology. 2016;44(10):833-53.

30. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983;148(3):839-43.

31. Hwang YC, Hayashi T, Fujimoto WY, Kahn SE, Leonetti DL, McNeely MJ, et al. Visceral abdominal fat accumulation predicts the conversion of metabolically healthy obese subjects to an unhealthy phenotype. International journal of obesity (2005). 2015;39(9):1365-70.

32. Bigaard J, Frederiksen K, Tjønneland A, Thomsen BL, Overvad K, Heitmann BL, et al. Body fat and fat-free mass and all-cause mortality. Obesity research. 2004;12(7):1042-9.

33. Amirabdollahian F, Haghighatdoost F. Anthropometric Indicators of Adiposity Related to Body Weight and Body Shape as Cardiometabolic Risk Predictors in British Young Adults: Superiority of Waist-to-Height Ratio. Journal of obesity. 2018;2018:8370304.

34. Li WC, Chen IC, Chang YC, Loke SS, Wang SH, Hsiao KY. Waist-to-height ratio, waist circumference, and body mass index as indices of cardiometabolic risk among 36,642 Taiwanese adults. Eur J Nutr. 2013;52(1):57-65.

35. Zhu Q, Shen F, Ye T, Zhou Q, Deng H, Gu X. Waist-to-height ratio is an appropriate index for identifying cardiometabolic risk in Chinese individuals with normal body mass index and waist circumference. J Diabetes. 2014;6(6):527-34.

36. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev. 2000;21(6):697-738.

37. Wium C, Eggesbø HB, Ueland T, Michelsen AE, Torjesen PA, Aukrust P, et al. Adipose tissue distribution in relation to insulin sensitivity and inflammation in Pakistani and Norwegian subjects with type 2 diabetes. Scand J Clin Lab Invest. 2014;74(8):700-7.

38. Varlamov O, Somwar R, Cornea A, Kievit P, Grove KL, Roberts CT, Jr. Single-cell analysis of insulin-regulated fatty acid uptake in adipocytes. American journal of physiology Endocrinology and metabolism. 2010;299(3):E486-96.

39. Perona JS, Schmidt Rio-Valle J, Ramirez-Velez R, Correa-Rodriguez M, Fernandez-Aparicio A, Gonzalez-Jimenez E. Waist circumference and abdominal volume index are the strongest anthropometric discriminators of metabolic syndrome in Spanish adolescents. Eur J Clin Invest. 2019;49(3):e13060.

40. Khan SH, Shahid R, Fazal N, Ijaz A. Comparison of Various Abdominal Obesity Measures for Predicting Metabolic Syndrome, Diabetes, Nephropathy, and Dyslipidemia. J Coll Physicians Surg Pak. 2019;29(12):1159-64.

41. Enzi G, Gasparo M, Biondetti PR, Fiore D, Semisa M, Zurlo F. Subcutaneous and visceral fat distribution according to sex, age, and overweight, evaluated by computed tomography. Am J Clin Nutr. 1986;44(6):739-46.

42. Borkan GA, Hults DE, Gerzof SG, Robbins AH, Silbert CK. Age changes in body composition revealed by computed tomography. Journal of gerontology. 1983;38(6):673-7.

43. Zaid M, Ameer F, Munir R, Rashid R, Farooq N, Hasnain S, et al. Anthropometric and metabolic indices in assessment of type and severity of dyslipidemia. J Physiol Anthropol. 2017;36(1):19.

44. Smith LG, Yatsuya H, Psaty BM, Longstreth WT, Jr., Folsom AR. Height and risk of incident intraparenchymal hemorrhage: Atherosclerosis Risk in Communities and Cardiovascular Health study cohorts. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association. 2013;22(4):323-8.

45. Gomez-Peralta F, Abreu C, Cruz-Bravo M, Alcarria E, Gutierrez-Buey G, Krakauer NY, et al. Relationship between "a body shape index (ABSI)" and body composition in obese patients with type 2 diabetes. Diabetol Metab Syndr. 2018;10:21.

46. Maessen MF, Eijsvogels TM, Verheggen RJ, Hopman MT, Verbeek AL, de Vegt F. Entering a new era of body indices: the feasibility of a body shape index and body roundness index to identify cardiovascular health status. PLoS One. 2014;9(9):e107212.

47. Haghighatdoost F, Sarrafzadegan N, Mohammadifard N, Asgary S, Boshtam M, Azadbakht L. Assessing body shape index as a risk predictor for cardiovascular diseases and metabolic syndrome among Iranian adults. Nutrition.
### Tables

**Table 1** Characteristics of the study participants according to gender among non-overweight/obese adults

| Variables                  | Total (n=2916) | Male (n=1215) | Female (n=1701) | P value  |
|----------------------------|----------------|--------------|-----------------|----------|
| Age (years)                | 47.04±10.38    | 47.91±10.70  | 46.41±10.11     | <0.001   |
| Education                  |                |              |                 |          |
| Low (<9y)                  | 711 (24.4%)    | 254 (20.9%)  | 457 (26.9%)     | <0.001   |
| Middle (9-12y)             | 1035 (35.5%)   | 439 (36.1%)  | 596 (35.0%)     | <0.001   |
| High (>12y)                | 1170 (40.1%)   | 522 (43.0%)  | 648 (38.1%)     | <0.001   |
| Height (cm)                | 164.06±7.96    | 170.78±5.89  | 159.26±5.36     | <0.001   |
| Weight (kg)                | 57.68±7.73     | 63.64±6.42   | 53.39±5.42      | <0.001   |
| WC (cm)                    | 77.33±7.42     | 82.08±5.87   | 73.95±6.49      | <0.001   |
| WHtR                       | 0.47±0.04      | 0.48±0.03    | 0.46±0.04       | <0.001   |
| BMI (kg/m²)                | 21.36±1.77     | 21.80±1.64   | 21.05±1.78      | <0.001   |
| AVI                        | 12.22±2.21     | 13.64±1.85   | 11.20±1.87      | <0.001   |
| ABSI                       | 0.0784±0.004   | 0.0805±0.0038| 0.0769±0.0049   | <0.001   |
| WWI                        | 10.20±0.64     | 10.30±0.54   | 10.13±0.70      | <0.001   |
| BRI                        | 2.87±0.71      | 3.03±0.61    | 2.76±0.75       | <0.001   |
| SBP (mmHg)                 | 116.55±15.97   | 119.18±14.46 | 114.68±16.72    | <0.001   |
| DBP (mmHg)                 | 69.42±10.48    | 72.20±10.30  | 67.44±10.16     | <0.001   |
| FBG (mmol/L)               | 5.18±0.90      | 5.31±1.08    | 5.09±0.74       | <0.001   |
| TC (mmol/L)                | 4.77±0.94      | 4.82±0.96    | 4.74±0.93       | 0.038    |
| TG (mmol/L)                | 1.38±1.18      | 1.63±1.45    | 1.21±0.91       | <0.001   |
| HDL-C (mmol/L)             | 1.34±0.33      | 1.23±0.31    | 1.43±0.32       | <0.001   |
| LDL-C (mmol/L)             | 2.62±0.72      | 2.70±0.73    | 2.57±0.72       | <0.001   |
| CRP (mg/L)                 | 1.17±3.04      | 1.43±3.91    | 0.99±2.19       | <0.001   |
| UA (umol/L)                | 316.74±79.67   | 374.34±71.46 | 275.60±56.31    | <0.001   |
| High BP level (n, %)       | 663 (22.7%)    | 307 (25.3%)  | 356 (20.9%)     | 0.006    |
| Abdominal obesity (n, %)   | 195 (6.7%)     | 101 (8.3%)   | 94 (5.5%)       | 0.003    |
| Dysglycemia (n, %)         | 188 (6.4%)     | 109 (9.0%)   | 79 (4.6%)       | <0.001   |
| High TG level (n, %)       | 630 (21.65%)   | 381 (31.4%)  | 249 (14.6%)     | <0.001   |
| Low HDL-C level (n, %)     | 389 (13.3%)    | 284 (23.4%)  | 105 (6.2%)      | <0.001   |
| MetS (n, %)                | 143 (4.9%)     | 92 (7.6%)    | 51 (3.0%)       | <0.001   |

WC waist circumference, WtHR waist-to-height ratio, BMI body mass index, AVI Abdominal Volume Index, ABSI a body shape index, WWI weight adjusted waist index, BRI body roundness index, SBP systolic blood pressure,
DBP diastolic blood pressure, FBG fasting blood glucose, TC total cholesterol, TG triglyceride, HDL-C HDL cholesterol, LDL-C LDL cholesterol, CRP C-reactive protein, UA uric acid, MetS metabolic syndrome. P value, means the differences between groups according to gender among non-overweight/obese adults.

Table 2 Partial correlations between anthropometric indices with metabolic variables

|       | WHtR  | BRI   | WWI   | AVI   | ABSI  |
|-------|-------|-------|-------|-------|-------|
| male  | coe   | P     | coe   | P     | coe   | P     |
| SBP   | 0.099 | 0.001 | 0.101 | <0.001| 0.029 | 0.307 | 0.1  | 0.001 | -0.008 | 0.769 |
| DBP   | 0.159 | <0.001| 0.159 | <0.001| 0.103 | <0.001| 0.158 | <0.001| 0.068  | 0.199 |
| FBG   | 0.137 | <0.001| 0.136 | <0.001| 0.096 | <0.001| 0.122 | <0.001| 0.06   | 0.036 |
| TG    | 0.177 | <0.001| 0.176 | <0.001| 0.146 | <0.001| 0.162 | <0.001| 0.112  | <0.001|
| HDL-C | -0.184| <0.001| -0.182| <0.001| -0.134| <0.001| -0.192| <0.001| -0.111 | <0.001|
| LDL-C | 0.103 | <0.001| 0.099 | 0.001 | 0.062 | 0.031 | 0.082 | 0.004 | 0.026  | 0.374 |

femal

|       | WHtR  | BRI   | WWI   | AVI   | ABSI  |
|-------|-------|-------|-------|-------|-------|
| SBP   | 0.111 | <0.001| 0.116 | <0.001| 0.088 | <0.001| 0.117 | <0.001| 0.076  | 0.002 |
| DBP   | 0.086 | <0.001| 0.09  | <0.001| 0.068 | 0.005 | 0.101 | <0.001| 0.063  | 0.01  |
| FBG   | 0.141 | <0.001| 0.15  | <0.001| 0.14  | <0.001| 0.134 | <0.001| 0.122  | <0.001|
| TG    | 0.205 | <0.001| 0.218 | <0.001| 0.203 | <0.001| 0.216 | <0.001| 0.183  | <0.001|
| HDL-C | -0.172| <0.001| -0.168| <0.001| -0.102| <0.001| -0.192| <0.001| -0.078 | 0.001 |
| LDL-C | 0.08  | 0.001 | 0.077 | 0.001 | 0.075 | 0.002 | 0.056 | 0.022 | 0.053  | 0.028 |

WtHR waist-to-height ratio, BRI body roundness index, WWI weight adjusted waist index, AVI Abdominal Volume Index, ABSI a body shape index, SBP systolic blood pressure, DBP diastolic blood pressure, FBG fasting blood glucose, TG triglyceride, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol. The partial correlation is adjusted for age, UA and CRP. Bold indicates the strongest related anthropometric indices for different metabolic variables.

Table 3 The correlation between MetS and its components with anthropometric indexes

|       | High BP | Dysglycemia | Low HDL-C | High TG | MetS |
|-------|---------|-------------|-----------|---------|------|
| male  | OR      | 95%CI       | OR        | 95%CI   | OR   | 95%CI | OR   | 95%CI | OR  | 95%CI |
| WHTR  | 1.263*  | 1.087-1.467 | 1.561*    | 1.230-1.981 | 1.303* | 1.12-1.516 | 1.727* | 1.487-2.006 | 1.235* | 1.788-3.106 |
| BRI   | 1.254#  | 1.082-1.453 | 1.522*    | 1.212-1.912 | 1.287* | 1.11-1.493 | 1.696* | 1.465-1.963 | 2.235* | 1.728-2.890 |
| WWI   | 1.089^  | 0.94-1.262  | 1.309*    | 1.046-1.639 | 1.226* | 1.056-1.422 | 1.523* | 1.319-1.759 | 1.738* | 1.362-2.217 |
| AVI   | 1.205#  | 1.046-1.388 | 1.441*    | 1.162-1.788 | 1.331* | 1.153-1.535 | 1.585* | 1.38-1.82  | 2.45*  | 1.898-3.163 |
| ABSI  | 0.981^  | 0.851-1.130 | 1.164*    | 0.941-1.441 | 1.208* | 1.047-1.393 | 1.343* | 1.173-1.537 | 1.607* | 1.276-2.205 |
| female|         |             |           |         |      |       |         |       |      |      |
| WHTR  | 1.253#  | 1.076-1.460 | 1.46#     | 1.125-1.893 | 1.442* | 1.149-1.811 | 1.634* | 1.384-1.929 | 2.812* | 2.003-3.948 |
| BRI   | 1.251#  | 1.079-1.451 | 1.432#    | 1.126-1.821 | 1.414# | 1.139-1.756 | 1.578* | 1.346-1.851 | 2.565* | 1.881-3.498 |
| WWI   | 1.197#  | 1.050-1.391 | 1.426#    | 1.114-1.827 | 1.212^ | 0.973-1.509 | 1.462* | 1.249-1.713 | 2.171* | 1.62-2.91 |
| AVI   | 1.213#  | 1.056-1.393 | 1.392#    | 1.115-1.737 | 1.49*  | 1.22-1.819  | 1.472* | 1.269-1.707 | 2.768* | 2.052-3.733 |
| ABSI  | 1.142^  | 0.991-1.315 | 1.362#    | 1.077-1.723 | 1.156^ | 0.938-1.425 | 1.313* | 1.132-1.523 | 2.068* | 1.567-2.728 |
WtHR waist-to-height ratio, BRI body roundness index, WWI weight adjusted waist index, AVI Abdominal Volume Index, ABSI a body shape index, BP blood pressure, TG triglyceride, HDL-C HDL cholesterol, MetS metabolic syndrome, OR odds ratio, 95% CI 95% confidence interval. *, indicates \( p<0.001 \). #, indicates \( p<0.05 \). ^, indicates \( p>0.05 \). The bold indicates the highest value of odds ratio among the indices. The binary logistic regression analyses are adjusted for age, UA, and CRP.

Table 4 AUC and its 95%CI for each body index according to MetS components

|       | High BP |     | Dysglycemia |     | Low HDL-C |     | High TG |     | MetS  |     |
|-------|---------|-----|-------------|-----|-----------|-----|---------|-----|-------|-----|
|       | AUC     | 95%CI | AUC         | 95%CI | AUC       | 95%CI | AUC     | 95%CI | AUC   | 95%CI |
| Male  |         |      |             |      |           |      |         |      |       |      |
| WtHR | 0.602*  | 0.574| **0.669** 0.641| 0.579* 0.543 | 0.633* 0.605 | 0.739* 0.691 |
|       | -0.630  |      | -0.695      |      | -0.616   |      | -0.660  |      | -0.787|      |
| BRI   | 0.602*  | 0.574| **0.669** 0.641| 0.579* 0.543 | 0.633* 0.605 | 0.739* 0.691 |
|       | -0.630  |      | -0.695      |      | -0.616   |      | -0.660  |      | -0.787|      |
| WWI   | 0.581*  | 0.552| 0.655* 0.627| 0.563* 0.527 | 0.598* 0.565 | 0.689* 0.636 |
|       | -0.609  |      | -0.682      |      | -0.599   |      | -0.632  |      | -0.742|      |
| AVI   | 0.571*  | 0.543| **0.617** 0.589| **0.591** 0.555 | **0.634** 0.606 | **0.743** 0.690 |
|       | 0.599   |      | -0.644      |      | -0.628   |      | -0.666  |      | -0.796|      |
| ABSI  | 0.540#  | 0.512| 0.608* 0.580| 0.561# 0.525 | 0.579* 0.550 | 0.663* 0.606 |
|       | -0.569  |      | -0.665      |      | -0.598   |      | -0.607  |      | -0.719|      |
| Female|         |      |             |      |           |      |         |      |       |      |
| WtHR | 0.688*  | 0.666| **0.713** 0.691| 0.605* 0.581 | **0.712** 0.690 | 0.817* 0.798 |
|       | -0.710  |      | -0.734      |      | -0.628   |      | -0.733  |      | -0.835|      |
| BRI   | 0.688*  | 0.666| **0.713** 0.691| 0.605* 0.581 | **0.712** 0.690 | 0.817* 0.798 |
|       | -0.710  |      | -0.734      |      | -0.628   |      | -0.733  |      | -0.835|      |
| WWI   | 0.688*  | 0.665| 0.705* 0.682| 0.556* 0.532 | 0.684* 0.661 | 0.768* 0.748 |
|       | -0.710  |      | -0.726      |      | -0.580   |      | -0.706  |      | -0.788|      |
| AVI   | 0.659*  | 0.636| 0.692* 0.669| **0.614** 0.590 | 0.690* 0.667 | **0.819** 0.800 |
|       | -0.682  |      | -0.713      |      | -0.637   |      | -0.712  |      | -0.837|      |
| ABSI  | 0.660*  | 0.637| 0.682* 0.660| 0.541^ 0.48- | 0.647* 0.623 | 0.744* 0.723 |
|       | -0.682  |      | -0.704      |      | -0.669   |      | -0.765  |      |      |

WtHR waist-to-height ratio, BRI body roundness index, WWI weight adjusted waist index, AVI Abdominal Volume Index, ABSI a body shape index, BP blood pressure, TG triglyceride, HDL-C HDL cholesterol, MetS metabolic syndrome. *, indicates \( p<0.001 \). #, indicates \( p<0.05 \). ^, indicates \( p>0.05 \). Bold indicates the maximum.
Table 5 Pairwise comparison for ROC curves for the identification of MetS

|        | WHtR-BRI | WHtR-ABSI | WHtR-AVI | WHtR-WWI | BRI-BRI | BRI-ABSI | BRI-AVI | BRI-WWI | ABSI-ABSI | ABSI-AVI | ABSI-WWI | AVI-WWI |
|--------|-----------|-----------|----------|----------|---------|----------|---------|---------|-----------|----------|----------|---------|
| Male   |           |           |          |          |         |          |         |         |           |          |          |         |
| Diff. AUC | 0.005    | 0.072    | 0.009   | 0.046   | 0.077   | 0.003   | 0.051  | 0.081  | 0.026    | 0.055    |         |         |
| SE     | 0.003    | 0.02     | 0.02    | 0.02    | 0.02    | 0.02    | 0.01   | 0.02   | 0.01     | 0.02     |         |         |
| P-value | 0.079  | **0.003** | 0.64   | **0.003** | **0.001** | 0.84  | **0.001** | **0.001** | 0.06   | **0.026** |         |         |
| Female |           |           |          |          |         |          |         |         |           |          |          |         |
| Diff. AUC | 0.001    | 0.072    | 0.003   | 0.048   | 0.073   | 0.002   | 0.049  | 0.075  | 0.024    | 0.051    |         |         |
| SE     | 0.002    | 0.03     | 0.02    | 0.02    | 0.03    | 0.02    | 0.02   | 0.02   | 0.02     | 0.03     |         |         |
| P-value | 0.70   | **0.001** | 0.88   | **0.006** | **0.007** | 0.93  | **0.004** | **0.001** | 0.12   | **0.049** |         |         |

AUC area under curve, SE standard error, WHtR waist-to-height ratio, BRI body roundness index, WWI weight adjusted waist index, AVI abdominal volume index, ABSI a body shape index. P-values marked in bold are significant.

Table 6 The optimal cut-off values and its sensitivity and specificity for identification of MetS

|       | male          | female         |
|-------|---------------|----------------|
|       | Cut-off | Sens | Spec | Cut-off | Sens | Spec |
| WHtR  | 0.571 | 0.609 | **0.760** | 0.49 | **0.766** | 0.745 |
| BRI    | 3.41  | 0.609 | **0.760** | 3.24 | 0.745  | 0.766 |
| WWI    | 10.57 | 0.609 | 0.724  | 10.56 | 0.686  | 0.75  |
| AVI    | 14.47 | **0.717** | 0.663  | 12.83 | 0.725  | **0.823** |
| ABSI   | 0.0813 | 0.652 | 0.591  | 0.0806 | 0.627  | 0.796  |

WHtR waist-to-height ratio, BRI body roundness index, WWI weight adjusted waist index, AVI abdominal volume index, ABSI a body shape index. Bold indicates the maximum specificity/sensitivity.